Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 3, 2009, Pages 827-831

  Kawohl, Wolfram ^a   Schneider, Frank ^b   Vernaleken, Ingo ^b   Neuner, Irene ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Antipsychotics; Aripiprazole; Atypical antipsychotics; D2 receptor; Tourette syndrome

Indexed keywords

ARIPIPRAZOLE; PROPRANOLOL DERIVATIVE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE TITRATION; FEMALE; GERMANY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; SWITZERLAND; TIC; DRUG EFFECT; RETROSPECTIVE STUDY;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RETROSPECTIVE STUDIES; TOURETTE SYNDROME;

EID: 77949530237     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701762544     Document Type: Article

References (34)

1. Albin RL, Mink JW. 2006. Recent advances in Tourette syndrome research. Trends Neurosci 29:175-182.
2. Bruun RD. 1988. The natural history of Tourette's syndrome. In: Cohen DJ, Bruun RD, Leckman JF, editors. Tourette's syndrome and tic disorders. Clinical understanding and treatment. New York: Wiley. pp 21-39.
3. Bubl E, Perlov E, Tebartz Van Elst L. 2006. Aripiprazole in patients with Tourette syndrome. World J Biol Psychiatry 7:123-125.
4. Burris KD, Molski TF, Xu C, et al. 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
5. Constant EL, Borras L, Seghers A. 2006. Aripiprazole is effective in the treatment of Tourette's disorder. Int J Neuropsycho-pharmacol 9:773-774.
6. Davies L, Stern JS, Agrawal N, Robertson MM. 2006. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 21:447-453
7. Dehning S, Riedel M, Muller N. 2005. Aripiprazole in a patient vulnerable to side effects. Am J Psychiatry 162:625.
8. Duane DD. 2006. Aripiprazole in childhood and adolescence for Tourette syndrome. J Child Neurol 21:358.
9. Farde L, Wiesel FA, Halldin C, Sedvall G. 1988. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76.
10. Fountoulakis KN, Siamouli M, Kantartzis S, Panagiotidis P, Iacovides A, Kaprinis GS. 2006. Acute dystonia with low-dosage aripiprazole in Tourette's disorder. Ann Pharmacother 40:775-777.
11. Gründer G, Landvogt C, Vernaleken I, et al. 2006. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31:1027-1035.
12. Hounie A, De Mathis A, Sampaio AS, Mercadante MT. 2004. [Aripiprazole and Tourette syndrome]. Rev Bras Psiquiatr 26:213.
13. Janouschek H, Vernaleken I, Boy C, et al. 2006. Das temporale und extrastriatale D2/D3-Rezeptor-Bindungsprofil von Aripi-prazol bei Patienten mit schizophrener oder schizoaffektiver Psychose. Der Nervenarzt 77:S160.
14. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. 2002. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137-140.
15. Kastrup A, Schlotter W, Plewnia C, Bartels M. 2005. Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol 25:94-96.
16. Kessler RM, Ansari MS, Riccardi P, et al. 2006. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31:1991-2001.
17. Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC. 2005. Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. J Child Adolesc Psychopharmacol 15:318-324.
18. Leckman JF, King RA, Cohen DJ. 1999. Tics and tic disorders. In: Leckman JF, Cohen DJ, editors. Tics, obsessions, compulsions: Developmental psychopathology and clinical care. New York: Wiley & Sons. pp 23-32
19. Leckman JF, Riddle MA, Hardin MT, et al. 1989. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573.
20. Mamo D, Kapur S, Shammi CM, et al. 2004. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818-825.
21. Mesulam MM, Petersen RC. 1987. Treatment of Gilles de la Tourette's syndrome: eight-year, practice-based experience in a predominantly adult population. Neurology 37:1828-1833.
22. Miranda CM, Castiglioni TC. 2007. [Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients.]. Rev Med Chil 135:773-776.
23. Muller N. 2004. Tics. In: Jahn T, editor. Bewegungsstorungen bei psychischen Erkrankungen Berlin. Heidelberg, New York: Springer. pp 215-231.
24. Murphy TK, Bengtson MA, Soto O, et al. 2005. Case series on the use of aripiprazole for Tourette syndrome. Int J Neurop-sychopharmacol 8:489-490
25. Padala PR, Qadri SF, Madaan V 2005. Aripiprazole for the treatment of Tourette's disorder. Prim Care Companion J Clin Psychiatry 7:296-299.
26. Rickards H, Robertson M. 2003. A controlled study of psycho-pathology and associated symptoms in Tourette syndrome. World J Biol Psychiatry 4:64-68.
27. Rothenberger A, Banaschewski T 2003. Tic-Storungen (F 95). In: Arbeitsgemeinschaft Medizinischer Fachgesellschaften (AWMF), editors. Leitlinien zu Diagnostik und Therapie von psychischen Storungen im Sauglings-, Kindes-und Jugendal-ter. Cologne: Deutscher Arzte Verlag. pp 311-317.
28. Sallee FR, Kurlan R, Goetz CG, et al. 2000. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299.
29. Seignot JN. 1961. [A case of tic of Gilles de la Tourette cured by R 1625.]. Ann Med Psychol 119:578-579.
30. Singer HS. 1997. Neurobiology of Tourette syndrome. Neurol Clin North Am 15:357-375.
31. Tanner CM, Goldman SM. 1997. Epidemiology of Tourette syndrome. Neurol Clin 15:395-402.
32. Vernaleken I, Siessmeier T, Buchholz HG, et al. 2004. High striatal occupancy of D2-like dopamine receptors by amisul-pride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 7:421-430
33. Yoo HK, Kim JY, Kim CY 2006. A pilot study of aripiprazole in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 16:505-506.
34. Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY. 2007. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 68:1088-1093.